Overview
The National Institutes of Health (NIH) is encouraging mechanistic research on how the human microbiome shapes host physiology in health and disease. The goal is to translate that science into interventions, prevention, detection, and prognosis, and to understand how the microbiome affects response to treatment.
Seven NIH Institutes and Centers participate, with interests ranging from chronic infections and autoimmune disease to eye disease, aging, oral health, and cancer. NIAID notes that it aims to enable small business participation in product development, which makes the NIH SBIR program a natural route for companies building microbiome-based products.
Key dates and funding
- Next SBIR due dates: January 5, 2027 and April 5, 2027 (5:00 PM local time of your organization)
- Application route: NIH, CDC and FDA Parent SBIR (R43/R44), PA-27-100, Clinical Trial Optional
- Project period: normally up to 6 months for Phase I and up to 2 years for Phase II
- Topic window: NIH lists this Highlighted Topic through January 15, 2028, so it can support more than one submission cycle
Budget guidelines in PA-27-100 vary by participating Institute or Center. Total costs (direct, indirect, and fee) normally stay within these amounts:
- National Institute of Allergy and Infectious Diseases (NIAID): Phase I $700,000, Phase II $3,000,000
- National Cancer Institute (NCI): Phase I $700,000, Phase II $2,500,000
- National Institute on Aging (NIA): Phase I $700,000, Phase II $3,000,000
- National Center for Complementary and Integrative Health (NCCIH): Phase I $700,000, Phase II SBA guideline
- National Eye Institute (NEI): Phase I $400,000, Phase II SBA guideline
- National Institute of Dental and Craniofacial Research (NIDCR): SBA guideline for both phases
- National Institute on Minority Health and Health Disparities (NIMHD): SBA guideline for both phases
Who is eligible?
Only United States small business concerns can apply through the NIH Parent SBIR announcement. In plain terms, your company must meet these requirements:
- A for-profit business with a place of business in the United States and no more than 500 employees, including affiliates
- Generally more than 50% owned and controlled by U.S. citizens or permanent residents, or by qualifying venture capital, hedge fund, or private equity owners under SBA rules
- The Principal Investigator is primarily employed by the small business at the time of award and for the duration of the project
- No foreign organizations, foreign components, or foreign subawards (unfunded foreign collaborators and foreign consultants are permitted)
- Companies selected for funding submit the SBA foreign affiliations disclosure during the Just-in-Time process
Focus areas by NIH Institute
NIAID: infections and immune-mediated disease
- Mechanistic studies of chronic infections such as recurrent C. difficile infection, recurrent urinary tract infection, and bacterial vaginosis
- Immune-mediated diseases including rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, lupus, and allergies
NCI: microbes and cancer
- How microbes and their metabolites influence tumor initiation, progression, and treatment response
- Preclinical models, 3D co-cultures, and tumor-on-chip platforms
NIA: microbial metabolites and aging
- Effects on gut and blood-brain barriers and cellular senescence
- Links to Alzheimer's disease and related dementias
- Prebiotic and probiotic interventions
NEI: the gut-eye connection
- Gut dysbiosis in age-related macular degeneration, diabetic retinopathy, and glaucoma
- Systems biology, multi-omics, and machine learning for risk models and biomarkers
NCCIH, NIDCR, and NIMHD
- NCCIH: fundamental science of natural products, probiotics, and prebiotics for conditions such as stress, anxiety, metabolic disorders, and GI dysfunction
- NIDCR: oral microbiome-directed therapies for caries, periodontitis, and oral cancers, including bacteriophage, small molecule, and commensal-based approaches
- NIMHD: listed as a participating Institute (contact the NIMHD scientific team for its interests)
How to apply
NIH Highlighted Topics are not funding opportunities on their own. Small businesses apply through the NIH, CDC and FDA Parent SBIR announcement (PA-27-100) and write the application to match the interests of at least one participating Institute or Center. Read the full NIH Highlighted Topic before you start.
- Register early: SAM.gov (which issues your UEI and can take six weeks or more), Grants.gov, eRA Commons (a Signing Official plus a PI account with a linked ORCID iD), and the SBA Company Registry (proof of registration is attached to the application)
- Talk to the program officer: the topic lists scientific contacts for each participating Institute, and ORWH (which does not award grants) is interested in sex influences on the microbiome when paired with an awarding Institute
- Check the budget: contact the participating Institute or Center early if you plan to request more than the SBA budget guideline
- Submit electronically: through NIH ASSIST, a system-to-system solution, or Grants.gov Workspace by 5:00 PM local time on January 5, 2027 or April 5, 2027
Is this a fit for your company?
This topic suits companies developing live biotherapeutics, phage or small molecule microbiome modulators, microbiome-based diagnostics and biomarkers, or research platforms such as organ-on-chip and co-culture models. The strongest applications pair a clear product goal with a mechanistic hypothesis about how the microbiome drives the disease.
If that sounds like your company, book a free funding fit call with BW&CO. Our team has helped secure $350M+ in non-dilutive funding and can tell you quickly whether this topic, and which Institute, is the right target for your January or April submission.
Frequently asked questions
Is the NIH microbiome Highlighted Topic a funding opportunity?
No. It is an NIH Highlighted Topic, which signals scientific interest but is not a notice of funding opportunity. Small businesses apply through the NIH Parent SBIR announcement (PA-27-100), with the next due dates on January 5, 2027 and April 5, 2027.
How much NIH SBIR funding is available for microbiome research?
Budget guidelines in PA-27-100 depend on the Institute. NIAID, NCI, and NIA allow up to $700,000 for Phase I; NIAID and NIA allow up to $3,000,000 for Phase II and NCI up to $2,500,000. NCCIH allows $700,000 for Phase I, NEI $400,000, and NIDCR and NIMHD follow the SBA guideline.
Which NIH Institutes participate in the microbiome topic?
NIAID, NCI, NIA, NEI, NCCIH, NIDCR, and NIMHD participate. ORWH also participates but does not award grants, so applications must align with at least one awarding Institute.
What microbiome research is NIH looking for?
Mechanistic studies of how the microbiome influences health and disease, translated into interventions, prevention, detection, and prognosis. Examples include chronic infections, autoimmune disease, eye disease, aging and dementia, oral disease, and cancer treatment response.
Who is eligible to apply through NIH SBIR?
U.S. for-profit small businesses with no more than 500 employees, majority owned and controlled by U.S. citizens or permanent residents (or qualifying investors under SBA rules), whose Principal Investigator is primarily employed by the company. Foreign organizations and foreign subawards are not allowed.
Can BW&CO help with an NIH SBIR application for this topic?
Yes. BW&CO helps small businesses choose the right NIH Institute, align the Specific Aims with the Highlighted Topic, and build a competitive SBIR application. The firm has helped clients secure $350M+ in non-dilutive funding. Book a free funding fit call to see if your technology is a match.